Anavex Life Sciences Corp (AVXL)

[XenaLives]

“The drugs are tried in [the] wrong population.
Again, by the time people [have] even…mild
dementia, they [have] already had neuronal loss,
tau aggregation, [and] amyloid plaques for a long
period of time. The disease starts anywhere
between 10 to 20 years before the first onset of
symptoms. If you really want to modify the disease,
you have to modify the disease pathology much in
advance of symptoms, and that’s where
biomarkers come in. You need to have good
biomarker that can predict who will develop AD in
future. An ideal study would be, you get
biomarkers, and if the biomarkers suggest/put you
at risk for developing AD in [the] future, that’s
where you give disease-modifying therapy.
Probably you need to give it for 10 to 15 years to
really see if it [is] efficacious or not.”
[US] KOL, August 2012

“I think the goal which is achievable [is] to make
the diagnosis earlier and to treat or to have drugs
which can stop the disease where it is. In this case,
if we have drugs which can stop cognitive decline,
[that] would be enough, even if does not cure the
disease. If we make the diagnosis early enough, it
would be good.”
[EU] KOL, September 2012

“Somebody needs to study them [drugs] in
asymptomatic patients who are destined to
develop AD in the future for them to really show
efficacy. If they really delay the diagnosis or
prevent it, in fact, they are going to be good
preventive therapy. I do not think they are going to
be [as] effective as treatment when you already
have symptoms.”
[US] KOL, August 2012

See Page 3-4 below:
https://www.marketresearch.com/product/sample-7805866.pdf